Could Moderna Make a Fortune With a COVID Vaccine for Kids?

Moderna (NASDAQ: MRNA) recently announced that it's testing COVID-19 vaccine mRNA-1273 in children between the ages of 6 months and 12 years. The biotech has already been conducting clinical studies evaluating its vaccine in teens. In this Motley Fool Live video recorded on March 17, 2021, Motley Fool contributors Keith Speights and Brian Orelli talk about how significant of a catalyst Moderna's COVID vaccine for kids might be and answer viewer questions about the biotech stock.

Continue reading

Source Fool.com